The Danish Parliament has officially passed legislation to make Denmark's medical cannabis program permanent. The new law, which takes effect on January 1, 2026, marks a significant step forward in securing long-term access to medical cannabis treatment for patients and providing regulatory stability for the medical cannabis business in Denmark.
Since 2018, Denmark has operated a Pilot Program for medical cannabis, which is scheduled to expire in December 2025. Through this initiative, Denmark has positioned itself as a European leader in prescription-based medical cannabis. According to the official evaluation of the Program, many patients have reported positive treatment outcomes when using medical cannabis as an alternative to conventional therapies.
In November 2024, the Danish Parliament decided to make the use of medical cannabis a permanent option, bringing clarity and long-term stability to the industry. Medical cannabis companies have welcomed the decision as a significant milestone for the industry.
On April 24, 2025, the Danish Parliament formally adopted "Bill L135" that establishes the permanent legislative framework for the medical use of cannabis. The law will take effect on January 1, 2026.
The political approval provides reassurance and predictability for patients who may have been concerned about the future of their treatment. The decision includes several improvements that will benefit patients. These include updated guidance from the Danish Medicines Agency to support doctors in confidently prescribing medical cannabis. In addition, the Danish Patient Safety Authority will revise the health criteria used in its recommendations regarding driving restrictions for patients undergoing cannabis treatment. Importantly, the 50% subsidy for medical cannabis products will remain unchanged under the new law.
Source: Stenocare